Preferred Label : nafronyl;

MeSH definition : A drug used in the management of peripheral and cerebral vascular disorders. It is claimed to enhance cellular oxidative capacity and to be a spasmolytic. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1310) It may also be an antagonist at 5HT-2 serotonin receptors.;

MeSH synonym : Naftidrofuryl;

CISMeF synonym : azupharma brand of naftidrofuryl oxalate; DiActane; menarini brand of naftidrofuryl oxalate; merck brand of nafronyl oxalate; merck lipha santé brand 2 of naftidrofuryl oxalate; ct-Arzneimittel brand of naftidrofuryl oxalate; ct arzneimittel brand of naftidrofuryl oxalate; NaftiPuren; alpharma brand of naftidrofuryl oxalate; ratiopharm brand of naftidrofuryl oxalate; hexal brand of naftidrofuryl oxalate; thérabel brand of naftidrofuryl oxalate; merck lipha santé brand 1 of naftidrofuryl oxalate; faes brand of naftidrofuryl oxalate; lipha brand of naftidrofuryl oxalate; abbott brand of naftidrofuryl oxalate;

DeCS synonym : G vatran; Praxil ne;

MeSH hyponym : praxilène; Nafti-Puren; azunaftil; praxilene; dusodril; nafti-ratiopharm; Nafronyloxalate; LS-121; Di-Actane; nafti von ct; naftilux; gévatran; naftilong; artocoron; Di Actane; Nafronyl Oxalate; Oxalate, Nafronyl; Naftifurin Oxalate; Oxalate, Naftifurin; Nafti Puren; Nafti Ratiopharm; NaftiRatiopharm; LS 121; LS121;

MeSH CAS label : 2-Furanpropanoic acid, tetrahydro-alpha-(1-naphthalenylmethyl)-, 2-(diethylamino)ethyl ester;

MeSH Related Number : 31329-57-4 (Nafronyl); nafronyloxalate; 5ADB8D9388;

Registry Number MeSH : 31329-57-4;

Related CAS MeSH : 5ADB8D9388 (Nafronyloxalate);

Wikipedia link : https://en.wikipedia.org/wiki/Nafronyl;

Codes EINECS : 250-572-2;

Is substance : O;

UNII : 42H8PQ0NMJ;

InChIKey : KBAFPSLPKGSANY-UHFFFAOYSA-N;

Details


Main resources

You can consult :

A drug used in the management of peripheral and cerebral vascular disorders. It is claimed to enhance cellular oxidative capacity and to be a spasmolytic. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1310) It may also be an antagonist at 5HT-2 serotonin receptors.

https://www.has-sante.fr/portail/jcms/c_2900186/fr/naftilux
https://www.has-sante.fr/portail/jcms/c_2900186/fr/naftilux-naftidrofuryl-vasodilatateur-peripherique
2019
false
false
false
France
administration, oral
insurance, health, reimbursement
treatment outcome
arterial occlusive diseases
intermittent claudication
lower extremity
naftidrofuryl
guidelines for drug use
evaluation of the transparency committee
nafronyl

---
https://www.has-sante.fr/jcms/p_3112654/fr/praxilene
2019
false
false
false
France
insurance, health, reimbursement
intermittent claudication
administration, oral
vasodilator agents
naftidrofuryl
arterial occlusive diseases
lower extremity
treatment outcome
evaluation of the transparency committee
praxilene
nafronyl
nafronyl

---
http://www.cochrane.org/fr/CD001368
2012
United Kingdom
France
French
meta-analysis
intermittent claudication
nafronyl
treatment outcome
vasodilator agents
french abstract

---
http://www.has-sante.fr/portail/jcms/c_449333/naftilux
http://www.has-sante.fr/portail/jcms/c_1198187/naftilux
http://www.has-sante.fr/portail/display.jsp?id=c_618052
http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-02/naftilux_18012012_avis_ct11217_ct11634.pdf
2012
France
French
nafronyl
vasodilator agents
naftidrofuryl
administration, oral
insurance, health, reimbursement
intermittent claudication
raynaud disease
cognition disorders
adult
aged
treatment outcome
Nafronyloxalate
evaluation of the transparency committee

---
http://www.cochrane.org/fr/CD002070
2012
false
true
false
United Kingdom
France
nafronyl
treatment outcome
review of literature
french abstract
lower extremity
Acute ischemia of the lower limbs
ischemia
nafronyl

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=60639052
2012
France
summary of product characteristics
package leaflet
tablets
nafronyl

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=67195461
2012
France
summary of product characteristics
package leaflet
tablets
nafronyl

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=67186035
2012
France
summary of product characteristics
package leaflet
tablets
nafronyl

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=63387763
2012
France
summary of product characteristics
package leaflet
tablets
nafronyl

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=60768652
2012
France
summary of product characteristics
package leaflet
nafronyl
tablets

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=65067139
2012
France
summary of product characteristics
package leaflet
nafronyl
capsules

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=60730064
2012
France
summary of product characteristics
package leaflet
nafronyl
tablets

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=69195392
2012
France
summary of product characteristics
package leaflet
nafronyl
capsules

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=69099668
2012
France
summary of product characteristics
package leaflet
tablets
nafronyl

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=67461225
2012
France
summary of product characteristics
package leaflet
tablets
nafronyl

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=62978247
2012
France
summary of product characteristics
package leaflet
tablets
nafronyl

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=60130742
2012
France
summary of product characteristics
package leaflet
tablets
nafronyl

---
http://www.cochrane.org/fr/CD002955
2011
false
false
false
United Kingdom
France
treatment outcome
alzheimer disease
vasodilator agents
meta-analysis
french abstract
dementia
nafronyl

---
http://www.has-sante.fr/portail/jcms/c_944577/praxilene-gevatran
http://www.has-sante.fr/portail/upload/docs/application/pdf/2010-04/praxilene_-_gevatran_-_ct-7713.pdf
2010
France
French
nafronyl
vasodilator agents
administration, oral
insurance, health, reimbursement
naftidrofuryl
intermittent claudication
treatment outcome
raynaud disease
adult
aged
cognition disorders
Nafronyloxalate
evaluation of the transparency committee

---
http://www.cochrane.org/fr/CD005478
2009
false
true
false
United Kingdom
France
treatment outcome
review of literature
french abstract
nafronyl
stroke

---
https://minerva-ebp.be/fr/article/476
2008
false
false
minerva-ebm.be
Belgium
French
intermittent claudication
nafronyl
vasodilator agents
treatment outcome
critical appraisal or critical reading

---
http://www.has-sante.fr/portail/display.jsp?id=c_618891
http://www.has-sante.fr/portail/upload/docs/application/pdf/ct-4962_di_actane.pdf
2007
France
French
capsules
vasodilator agents
nafronyl
administration, oral
insurance, health, reimbursement
naftidrofuryl
intermittent claudication
raynaud disease
cognition disorders
adult
aged
Nafronyloxalate
evaluation of the transparency committee

---
http://www.has-sante.fr/portail/display.jsp?id=c_449307
2006
France
evaluation of the transparency committee
nafronyl
capsules
tablets

---
http://www.has-sante.fr/portail/display.jsp?id=c_449317
2006
France
evaluation of the transparency committee
tablets
nafronyl
capsules

---
http://www.has-sante.fr/portail/display.jsp?id=c_449328
2006
France
evaluation of the transparency committee
nafronyl
tablets

---
http://www.has-sante.fr/portail/display.jsp?id=c_449302
2006
France
evaluation of the transparency committee
nafronyl
tablets

---
Nous contacter.
26/04/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.